Andra AP fonden purchased a new stake in Baxter International Inc (NYSE:BAX) during the 1st quarter, HoldingsChannel reports. The institutional investor purchased 87,800 shares of the medical instruments supplier’s stock, valued at approximately $7,139,000.

A number of other large investors have also bought and sold shares of BAX. Horrell Capital Management Inc. raised its position in shares of Baxter International by 0.4% during the 1st quarter. Horrell Capital Management Inc. now owns 31,167 shares of the medical instruments supplier’s stock worth $2,534,000 after purchasing an additional 138 shares during the last quarter. Berman Capital Advisors LLC raised its position in shares of Baxter International by 8.5% during the 1st quarter. Berman Capital Advisors LLC now owns 1,793 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 141 shares during the last quarter. Brookmont Capital Management raised its position in shares of Baxter International by 3.7% during the 4th quarter. Brookmont Capital Management now owns 4,048 shares of the medical instruments supplier’s stock worth $266,000 after purchasing an additional 146 shares during the last quarter. Parsons Capital Management Inc. RI raised its position in shares of Baxter International by 0.4% during the 1st quarter. Parsons Capital Management Inc. RI now owns 33,782 shares of the medical instruments supplier’s stock worth $2,747,000 after purchasing an additional 146 shares during the last quarter. Finally, Citizens Financial Group Inc RI raised its position in shares of Baxter International by 6.4% during the 1st quarter. Citizens Financial Group Inc RI now owns 2,437 shares of the medical instruments supplier’s stock worth $198,000 after purchasing an additional 146 shares during the last quarter. 84.03% of the stock is currently owned by institutional investors.

Several research firms recently weighed in on BAX. Wells Fargo & Co upped their price target on shares of Baxter International from $80.00 to $89.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 3rd. JPMorgan Chase & Co. upped their price target on shares of Baxter International from $80.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, May 13th. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a research report on Wednesday, April 24th. Cowen set a $75.00 price objective on shares of Baxter International and gave the company a “hold” rating in a report on Monday, April 22nd. Finally, Barclays increased their price objective on shares of Baxter International from $72.00 to $75.00 and gave the company an “equal weight” rating in a report on Monday, April 15th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $78.33.

Shares of NYSE BAX opened at $77.97 on Thursday. The company has a market cap of $39.58 billion, a PE ratio of 25.56, a PEG ratio of 1.83 and a beta of 0.94. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.83 and a quick ratio of 1.30. Baxter International Inc has a 1 year low of $61.05 and a 1 year high of $82.25.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.08. The business had revenue of $2.63 billion during the quarter, compared to the consensus estimate of $2.61 billion. Baxter International had a net margin of 14.27% and a return on equity of 20.04%. The business’s revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.70 EPS. On average, sell-side analysts expect that Baxter International Inc will post 3.32 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Stockholders of record on Friday, June 7th will be issued a dividend of $0.22 per share. The ex-dividend date is Thursday, June 6th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.13%. This is an increase from Baxter International’s previous quarterly dividend of $0.19. Baxter International’s dividend payout ratio (DPR) is currently 28.85%.

In other news, SVP Giuseppe Accogli sold 38,297 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $76.78, for a total transaction of $2,940,443.66. Following the completion of the sale, the senior vice president now owns 70,001 shares in the company, valued at approximately $5,374,676.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas T. Stallkamp sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $76.20, for a total transaction of $76,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 5,054,687 shares of company stock valued at $386,108,579 in the last 90 days. Insiders own 0.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/andra-ap-fonden-purchases-shares-of-87800-baxter-international-inc-nysebax/3039972.html.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: Purposes and Functions of the Federal Reserve

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.